Global Piston Seals Market Revenue Share to Exceed USD 3.4 Billion Mark by 2033, Growing Steadily at 3.8% CAGR | FMI Analysis

The global piston seals market is positioned for substantial growth, establishing a robust foundation in 2022 with an estimated value of USD 2.2 billion. Primed for notable evolution, the market is projected to witness a surge from its 2023 valuation of USD 2.3 billion, ultimately surpassing an impressive USD 3.4 billion by 2033. This growth trajectory is supported by a steady Compound Annual Growth Rate (CAGR) of 3.8% over the coming decade.

An intriguing aspect of these forward-looking projections is the enduring prominence of double-acting piston seals. According to insights from Future Market Insights, the double-acting piston seals segment is anticipated to maintain a consistent 3.5% CAGR through 2033. Renowned for their effectiveness in sealing fluid pressure in both directions, these seals have solidified their position as market leaders, characterized by reliability and versatility.

Piston seals have emerged as crucial components within machinery due to their integral role in preventing leakage. These seals are typically crafted from materials like nitrile rubber, polyamide, PTFE, and thermos-plastic polyurethane.

A significant advantage of these hydraulic seals is their ability to diminish friction between the piston and the cylinder wall by providing a slick surface. The absence of piston seals elevates the risk of hydraulic cylinder or system failure.

The significance of piston seals lies in their capacity to ensure that pressurized fluid doesn’t bypass the piston, especially when the system pressure propels the piston along the cylinder. These seals are primarily designed to accommodate the back-and-forth movements typical of applications involving cylinders in both pneumatic and hydraulic systems.

Influential Factors Shaping the Market:

  • The global piston seals industry is set to thrive due to the substantial growth anticipated in key sectors like automotive, aerospace, and power generation, among others.
  • The heightened need for effective leakage protection solutions in machines with reciprocating motion, such as hydraulic pumps and cylinders, is expected to drive an upswing in piston seal sales.
  • A promising trend in the market is the growing preference for tailor-made piston seal solutions, presenting manufacturers with appealing opportunities.
  • The increasing utilization of piston seals in heavy machinery is poised to play a pivotal role in expanding the market’s reach.
  • With the ongoing rapid pace of industrialization, the prospects for piston seal companies are anticipated to be notably favorable, opening doors for growth and development.

Competitive Landscape:

Prominent players in the piston seal manufacturing sector, as highlighted in the report, encompass industry leaders such as All Seals Inc., Boca Bearings, Inc., ElringKlinger AG, ElringKlinger Kunststofftechnik GmbH, Evco Seals, Kastas Sealing Technologies A.S., MSP Seals, Inc., SKF Group, SPC Group, and Garlock Sealing Technologies.

These esteemed companies are strategically focusing on innovation to address evolving end-user requirements, ultimately bolstering their revenue streams. Their endeavors encompass a range of strategic initiatives, including forging partnerships, pursuing mergers, expanding facilities, entering distribution agreements, executing acquisitions, and fostering collaborations. These actions are geared towards securing a competitive advantage within the market.

Recent Noteworthy Developments:

  • In March 2023, Hallite introduced the Hallite 777 double-acting piston seal at the IFPE event. This compact seal is meticulously designed for medium to heavy-duty applications across diverse industries, showcasing the company’s commitment to advanced solutions.
  • In November 2022, the SKF Group successfully finalized the acquisition of Tenute Srl., a prominent developer and manufacturer of sealing solutions for various industrial applications. Notably, this acquisition has led to the introduction of a new seal, featuring cost-effective material options tailored for less demanding applications, effectively diversifying their product portfolio.

Key Segments Covered:

By Type:

  • Double-acting
  • Single-acting
  • Custom Designed

By End Use:

  • Automotive
  • Heavy Machinery
  • General Engineering
  • Aerospace

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Access Report Details for More In-Depth Information!

Author:

Nikhil Kaitwade (Associate Vice President at Future Market Insights, Inc.) has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.

His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.

Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Endometriosis Treatment Market Oral Contraceptives Remain a Preferred Treatment for Pelvic Pain and Endometriosis, Despite Potential Side Effects

Endometriosis Treatment Market
Endometriosis Treatment Market

The Endometriosis Treatment Market is charting a course for stable expansion, fueled by growing awareness and a rise in diagnosed cases. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the market is projected to exhibit a Compound Annual Growth Rate (CAGR) of approximately 3% from 2019 to 2030. This consistent growth trajectory is expected to propel the market valuation to surpass US$4 billion by the end of the forecast period, reflecting a significant increase from US$2.8 billion in 2018.

The steadfast growth of this industry is propelled by the escalating prevalence of endometriosis, a condition affecting millions of women worldwide. As the demand for advanced treatment options continues to surge, industry leaders are taking the helm, focusing on pioneering therapeutic advancements and strategic product launches.

Key Takeaways of Endometriosis Treatment Market Study

  • Based on the drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to a high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing the recurrence of pelvic pain and endometriosis lesions.
  • High treatment efficacy and acceptance with low risk are expected to result in a notable share of hormonal therapy in the treatment type.
  • The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of the value share of the endometriosis treatment industry, owing to the high patient pool in hospitals and visiting retail pharmacies.
  • Europe captured a notable revenue share of 37% in 2018 and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
  • Increasing government expenditure for the high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment industry across this region.

Oral contraceptives continue to be a highly preferred first-line treatment for patients with pelvic pain and endometriosis, particularly for those without contraindications. Known for their effectiveness in preventing the recurrence of pelvic pain and the growth of endometriosis lesions, these medications offer significant relief for many women suffering from these conditions.

However, while oral contraceptives are widely used, they are not without potential side effects. Patients may experience mood changes, nausea, and elevated blood pressure levels, which can affect their quality of life. These side effects should be carefully considered by healthcare providers when recommending oral contraceptives to patients.

Progestins as an Alternative Treatment
In contrast to oral contraceptives, progestins—another form of hormonal therapy—require periodic consumption rather than the regular daily use of oral contraceptives. While progestins may offer benefits in managing symptoms of endometriosis and pelvic pain, they also come with their own set of considerations and should be used as part of a comprehensive treatment plan tailored to the patient’s needs.

Key Considerations for Treatment Choices:

  • Efficacy vs. Side Effects: While oral contraceptives are effective in managing endometriosis, it’s important for patients and healthcare providers to weigh the benefits against potential side effects.
  • Personalized Treatment Plans: As treatment options evolve, a more personalized approach that considers the patient’s health profile, symptom severity, and lifestyle is essential.
  • Alternative Therapies: Progestins and other therapies should be discussed as potential alternatives for patients who may experience intolerable side effects from oral contraceptives.

Grab Your Complete Report Instantly

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

By Drug:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

By Treatment Type:

  • Hormonal Therapy
  • Pain Management

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • e-Commerce

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Psoriatic Arthritis Treatment Market to Reach USD 25,375.6 Million by 2034, Growing at a 7.8% CAGR

Psoriatic Arthritis (PsA) Treatment Industry
Psoriatic Arthritis (PsA) Treatment Industry

The global psoriatic arthritis (PsA) treatment market, valued at USD 11,973.7 million in 2024, is projected to experience significant growth over the next decade. With a Compound Annual Growth Rate (CAGR) of 7.8%, the market is expected to reach a valuation of USD 25,375.6 million by 2034.

The growing prevalence of psoriatic arthritis, a chronic autoimmune condition that affects the joints and skin, is a primary factor driving the market expansion. Advances in biologic therapies, which offer targeted treatments for PsA, are significantly improving patient outcomes and fueling demand for more effective solutions.

The increasing awareness of PsA, coupled with the rising adoption of advanced therapies, including tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, is expected to further boost the market. The growing focus on personalized treatments and a better understanding of PsA pathophysiology are also contributing to market growth.

As healthcare systems focus on improving management options for chronic inflammatory diseases, the PsA treatment market is set to experience sustained growth, addressing unmet needs for effective and long-term treatments.

Key Growth Drivers

The growth of the PsA treatment market is driven by several factors:

  • Rising Prevalence of Psoriatic Arthritis: With approximately 125 million people affected by psoriasis globally, the incidence of psoriatic arthritis is also increasing, leading to higher demand for effective treatments.
  • Advancements in Treatment Options: The introduction of new biologics and targeted therapies, such as interleukin inhibitors, has improved clinical outcomes and quality of life for patients.

Market Dynamics

  • The market is characterized by a variety of treatment options, including biologics, disease-modifying antirheumatic drugs (DMARDs), and corticosteroids. Biologics are expected to capture a significant share due to their efficacy and safety profile.
  • Increased awareness about the importance of early diagnosis and treatment is likely to further drive market growth.

Regional Insights

  • North America is expected to dominate the market, accounting for a substantial share due to the presence of major pharmaceutical companies and high adoption rates of advanced therapies.
  • The Asia-Pacific region is anticipated to be the fastest-growing market, fueled by improving healthcare infrastructure and rising healthcare spending in countries like China and India.

Competitive Landscape in the Psoriatic Arthritis (PsA) Treatment Market

The development of new drugs remains a priority for players. In addition, collaborative strategies are also part of the vision. Partnerships with public bodies are sought to raise awareness about the disease.

The need for developing novel drug options is evident when looking at an industry giant like Pfizer Inc.

The company also partners with other healthcare sector players for the development of new drugs. Johnson and Johnson also concentrate on new drug development, investing significant amounts into trials.

Recent Developments in the Psoriatic Arthritis (PsA) Treatment Market

In September 2023, Wellmin Health, in collaboration with the non-profit organization Versus Arthritis, launched the Pathway platform. It is a program developed to help patients with arthritis, including psoriatic arthritis.

In February 2024, Biocon Biologics announced that it had reached an agreement with Janssen Biotech Inc. and Johnson & Johnson to commercialize the drug Bmab 1200.

Grab Your Complete Report Instantly

Key Companies in the Psoriatic Arthritis (PsA) Treatment Market

Key companies in the industry include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, UCB S.A., Eli Lilly & Co, Novartis AG, Celgene Corporation, and AstraZeneca PLC.

Key Segments of Psoriatic Arthritis (PsA) Treatment Market

By Drug Type:

Based on the drug type, the psoriatic arthritis (PsA) treatment market can be segmented into the following segments: non-steroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs, and biologics.

Disease-modifying anti-rheumatic drugs can be further separated into corticosteroids, antimalarial, methotrexate, and others. On the other hand, biologics can be bifurcated into TNF inhibitors and interleukin inhibitors.

By Route of Administration:

Based on the route of administration, the psoriatic arthritis (PsA) treatment market can be bifurcated into the following segments: injectable and oral.

By Distribution Channel:

Based on the distribution channel, the psoriatic arthritis (psa) treatment market can be segmented into the following segments: hospital pharmacies, retail pharmacies, and mail-order pharmacies.

By Region:

The sector has been analyzed with the following regions covered: North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Antibiotic Susceptibility Testing Market to Reach USD 4.05 Billion by 2028, Growing at 5.2% CAGR

Antibiotic Susceptibility Testing Market
Antibiotic Susceptibility Testing Market

The global antibiotic susceptibility testing market, valued at USD 2.82 billion in 2021, is anticipated to witness steady growth over the forecast period. Expanding at a Compound Annual Growth Rate (CAGR) of 5.2%, the market is projected to reach a valuation of USD 4.05 billion by 2028.

The rising prevalence of antibiotic-resistant infections worldwide is driving the demand for reliable susceptibility testing methods. These tests help determine the most effective antibiotics for treating infections, improving patient outcomes, and combating the growing threat of antimicrobial resistance (AMR).

Technological advancements in diagnostic tools, including automated testing systems and rapid diagnostic kits, are further boosting market expansion. Increased focus on precision medicine and stringent regulations promoting judicious antibiotic use are also contributing to the adoption of susceptibility testing across healthcare settings.

As global healthcare systems prioritize combating AMR, the antibiotic susceptibility testing market is set to play a crucial role in enabling effective infection management and safeguarding public health.

Key Growth Drivers

The growth of the antibiotic susceptibility testing market can be attributed to several factors:

  • Increasing Incidence of Infectious Diseases: The rising occurrence of infections caused by antibiotic-resistant bacteria is driving the demand for effective susceptibility testing to guide treatment decisions.
  • Growing Awareness of Antimicrobial Resistance (AMR): Increased awareness among healthcare professionals and the public regarding AMR has led to a greater emphasis on accurate diagnostic testing.

Market Dynamics

  • The market includes various testing methods, such as disk diffusion, Etest, and automated systems, which are essential for determining the efficacy of antibiotics against specific pathogens.
  • The adoption of automated systems is expected to grow rapidly due to their ability to provide faster and more accurate results compared to traditional methods.

Regional Insights

  • North America is anticipated to hold the largest share of the antibiotic susceptibility testing market, driven by advanced healthcare infrastructure and significant investments in research and development.
  • The Asia-Pacific region is expected to experience the fastest growth due to increasing healthcare needs and rising awareness about infection control measures.

Competitive Landscape

Leading market players have upgraded their manufacturing facilities and are engaged in a variety of R&D activities. Regulatory approvals, high-tech products, introduction of new products, acquisitions, and collaborative partnerships with other companies are all priorities for key providers of antibiotic susceptibility testing systems.

For instance,

  • Alifax launched a ground-breaking proper system for rapid bacteria detection that gives antibiotic susceptibility and resistance testing in six hours and needs less manual labour, based on the rapid phenotyping method.

Key Companies Profiled

BD; Danaher; Thermo Fisher Scientific; Bio-Rad; Creative Diagnostics; Accelerate Diagnostics; Alifax; Roche Diagnostics Limited; Merck Group; Synbiosis; MP Biomedicals; QuantaMatrix Inc.; Resistell AG

Get the Comprehensive Full Report Now

Key Segments Of Antibiotic Susceptibility Testing Industry Survey

Antibiotic Susceptibility Testing Market by Product:

  • Instruments
    • Automated Broth Microdilution Systems
    • Manual Broth Microdilution Systems
    • Semi-automated Broth Microdilution Systems
  • Software & Services
    • Image & Analysis Software
    • Installation Services
  • Kits & Reagents

Antibiotic Susceptibility Testing Market by Application:

  • Sepsis
  • Respiratory Infections
  • Gastrointestinal Infections
  • Meningitis & Encephalitis
  • Endocarditis
  • Others

Antibiotic Susceptibility Testing Market by End User:

  • Diagnostic Laboratories
  • Hospitals
  • Research Laboratories

Antibiotic Susceptibility Testing Market by Region:

  • North America Antibiotic Susceptibility Testing Market
  • Latin America Antibiotic Susceptibility Testing Market
  • Europe Antibiotic Susceptibility Testing Market
  • East Asia Antibiotic Susceptibility Testing Market
  • South Asia & Pacific Antibiotic Susceptibility Testing Market
  • Middle East & Africa (MEA) Antibiotic Susceptibility Testing Market

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Radiation-Induced Myelosuppression Treatment Market to Reach USD 3.5 Billion by 2028, Growing at 3.1% CAGR

Global Radiation-Induced Myelosuppression Treatment Industry
Global Radiation-Induced Myelosuppression Treatment Market

The global radiation-induced myelosuppression treatment market, valued at USD 2.9 billion in 2022, is expected to grow steadily over the forecast period. Expanding at a Compound Annual Growth Rate (CAGR) of 3.1%, the market is projected to reach a valuation of USD 3.5 billion by 2028.

The rising incidence of cancer and the increasing use of radiation therapy as a treatment option are key drivers of the market. Radiation-induced myelosuppression, a common side effect of radiation therapy, leads to reduced blood cell production in the bone marrow, necessitating effective treatments to manage and mitigate its impact.

Advancements in supportive care, including novel pharmaceuticals and biologics, are enhancing the management of myelosuppression. Increased focus on improving patient outcomes and reducing therapy-related complications is further contributing to market growth.

With ongoing research and development initiatives and growing awareness among healthcare providers, the radiation-induced myelosuppression treatment market is expected to witness sustained demand over the coming years.

Key Growth Drivers

Several factors are driving the growth of the radiation-induced myelosuppression treatment market:

  • Increasing Cancer Burden: The rising incidence of cancer and the widespread use of radiation therapy are significant contributors to the demand for treatments addressing radiation-induced myelosuppression.
  • Advancements in Healthcare Infrastructure: Improvements in healthcare facilities and treatment protocols are enhancing patient outcomes and increasing the adoption of effective therapies.

Market Dynamics

  • Indications and Treatments: Neutropenia is expected to generate the highest demand within this market, with injectable treatments holding a substantial share of the overall market value.
  • Emerging Opportunities: Conditions such as thrombocytopenia and anemia present additional opportunities for treatment providers, as they are common complications associated with radiation therapy.

Regional Insights

  • The North American region is anticipated to dominate the market, accounting for over 65% of the global market value due to a strong presence of established healthcare systems and ongoing research and development activities.

Competition Landscape

Leading players operating in the global radiation-induced myelosuppression treatment market are investing in research and development to improve lines of treatment for myelosuppression treatment. In addition to this, players are investing in mergers and acquisitions to strengthen their distribution channels.

Key Companies Profiled

Amgen Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; Mylan N.V.; Pfizer Inc.; Janssen Global Services, LLC (Johnson & Johnson); Partner Therapeutics, Inc.; Mission Pharmacal Company; Myelo Therapeutics GmbH; Pluristem Therapeutics Inc.

Access the Full Report

Radiation-Induced Myelosuppression Treatment Market by Category

Indication:

  • Neutropenia
  • Anemia
  • Thrombocytopenia

Drug Class:

  • Growth factors
  • Erythropoietin stimulating agents
  • Thrombopoietic agents
  • Iron supplements

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Drug stores

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Onychomycosis Treatment Market to Reach USD 10.6 Billion by 2033, Growing at 8.4% CAGR

Onychomycosis Treatment Market
Onychomycosis Treatment Market

The global onychomycosis treatment market is poised for robust growth, with an estimated valuation of USD 4,738.3 million in 2023. Over the forecast period from 2023 to 2033, the market is anticipated to expand at a Compound Annual Growth Rate (CAGR) of 8.4%, reaching a projected value of USD 10,608.8 million by 2033.

The market’s expansion is largely driven by the rising prevalence of diabetes, which significantly increases susceptibility to nail fungal infections. Onychomycosis, a common fungal infection affecting nails, is a growing concern among diabetic and aging populations worldwide.

Increased awareness about nail health, coupled with advancements in treatment options such as topical antifungal medications, oral therapies, and laser treatments, is further bolstering market growth. The development of effective and non-invasive treatment methods is expected to enhance patient outcomes and drive demand over the coming years.

As the healthcare industry continues to focus on addressing lifestyle-related diseases and their complications, the onychomycosis treatment market is set to experience sustained growth.

Key Growth Drivers

The growth of the onychomycosis treatment market can be attributed to several factors:

  • Increasing Prevalence of Diabetes: The rising incidence of diabetes significantly increases the risk of developing nail fungal infections, driving demand for effective treatment options.
  • Aging Population: As the global population ages, older individuals are more susceptible to circulatory issues and weakened immune systems, making them more vulnerable to onychomycosis.

Market Dynamics

  • The market is expected to benefit from advancements in treatment options, including new antifungal medications and innovative delivery methods such as topical treatments and nail lacquers.
  • Increased awareness about fungal nail infections and their implications on overall health is likely to boost market growth as more individuals seek treatment.

Regional Insights

  • North America is anticipated to dominate the market due to a well-developed healthcare infrastructure and a high prevalence of skin infections.
  • The Asia-Pacific region is also expected to witness substantial growth, driven by rising healthcare expenditures and increasing awareness about onychomycosis.

Competition Analysis

Key players in the global onychomycosis treatment market include Teva Pharmaceutical Industries Ltd., Sanofi S.A., Valent Pharmaceutical, Galderma, Johnson & Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health, Inc., Pfizer Inc., Almirall, S.A., Bayer AG, Viatris Inc., GlaxoSmithKline plc, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd.

Recent Developments in the Market Include

  • In November 2021, Sanofi announced the acquisition of Kadmon Holdings. The acquisition further develops the growth and expansion of the General Medicines portfolio. Sanofi concluded its acquisition of Kadmon through the merger of a wholly owned subsidiary of Sanofi with and into Kadmon, pursuant to Section 251 of the General Corporation Law of the State of Delaware, with Kadmon continuing as the surviving corporation and becoming an indirect, wholly-owned subsidiary of Sanofi.
  • In December 2021, Pfizer Inc. and Arena Pharmaceuticals, Inc. announced that the companies had inked an agreement under which Pfizer may acquire Arena, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Key Companies Profiled

Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; Medimetriks Pharmaceuticals, Inc.; Galderma; Johnson & Johnson; Novartis AG; Moberg Pharma AB; Cardinal Health, Inc.; Pfizer Inc.; Almirall, S.A.; Bayer AG; Viatris Inc.; GlaxoSmithKline plc; Cipla Ltd.; Dr. Reddy’s Laboratories Ltd

Get Complete Full Report

Key Segments in The Global Onychomycosis Treatment Industry

Treatment Type:

  • Drugs
    • Oral
      • Rx
      • OTC
    • Topical
      • Rx
      • OTC
  • Lasers
    • C02 Ablative Lasers
    • Nd: YAG Lasers
    • Dual-wavelength near-infrared Lasers
  • Photodynamic Therapy

Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

Age Group:

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

Gender:

  • Male
  • Female

Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Dermatology Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies & Online Sales

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Therapeutic Nuclear Medicine Market to Reach USD 1.97 Billion by 2034, Growing at a CAGR of 4.10%

Therapeutic Nuclear Medicines Market
Therapeutic Nuclear Medicines Market

The global therapeutic nuclear medicine market, valued at USD 1.32 billion in 2024, is poised for significant growth over the next decade. Projected to expand at a Compound Annual Growth Rate (CAGR) of 4.1% from 2024 to 2034, the market is expected to reach a valuation of USD 1.97 billion by 2034.

The growth of the therapeutic nuclear medicine market is driven by increasing adoption of targeted radiopharmaceutical therapies for cancer and other chronic diseases. These therapies offer precision treatment by delivering radioactive isotopes directly to affected tissues, minimizing damage to surrounding healthy cells.

Key factors fueling market expansion include advancements in nuclear medicine technology, rising prevalence of cancer and cardiovascular diseases, and increasing investment in radiopharmaceutical R&D. Regulatory support for innovative therapies and expanding applications in personalized medicine are further boosting the market outlook.

As healthcare systems worldwide focus on precision oncology and tailored treatments, the therapeutic nuclear medicine market is set for sustained growth, offering promising solutions for complex medical conditions.

Key Growth Drivers

The growth of the therapeutic nuclear medicine market is influenced by several factors:

  • Increasing Incidence of Cancer: The rising number of cancer cases globally is a significant driver, as therapeutic nuclear medicine plays a crucial role in treating various cancers, particularly thyroid cancer.
  • Advancements in Nuclear Medicine Technology: Innovations in radiopharmaceuticals and imaging techniques are enhancing the effectiveness and safety of nuclear medicine therapies.

Market Dynamics

  • The market is characterized by the use of radioactive materials for both diagnostic and therapeutic purposes, with a growing emphasis on personalized medicine.
  • Increased awareness and acceptance of nuclear medicine therapies among healthcare providers and patients are contributing to market expansion.

Regional Insights

  • North America is expected to dominate the therapeutic nuclear medicine market due to high healthcare spending, advanced medical infrastructure, and strong research and development activities.
  • Emerging markets in Asia-Pacific may experience significant growth driven by increasing healthcare investments and a rising burden of cancer-related diseases.

Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market

The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.

Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.

Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.

Recent Developments in the Therapeutic Nuclear Medicine Market

  • In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
  • In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
  • In January 2024, BARC’s Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India’s Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
  • In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.

Key Companies in the Therapeutic Nuclear Medicine Market

  • Bayer AG
  • GE Healthcare
  • Novartis AG
  • Cardinal Health Inc.
  • Mallinckrodt plc.
  • Lantheus Medical Imaging Inc.
  • Bracco Imaging S.p.A
  • Eckert & Ziegler
  • Curium Pharma
  • International Isotopes Idaho, Inc.
  • Medi-Radiopharma Co., Ltd.

A Full Report Overview

Key Segments

By Treatment Type:

  • Radium-223
  • Iodine-131
  • Leutitium-177
  • Yttrium-90
  • Samarium-153
  • Strontium-89
  • Rhenium-188+Rhenium-186
  • Erbium- 169
  • Phosphorous-32
  • Others

By Indication:

  • Prostate Cancer
  • Painful Bone Metastases
  • Thyroid Cancer
  • Neuroblastoma
  • Synovitis
  • Non-Hodgkin’s Lymphoma
  • Hepatic Metastases
  • Brain Tumour
  • Others

By Distribution Channel:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Therapeutic Nuclear Medicine Market to Reach USD 1.97 Billion by 2034, Growing at a CAGR of 4.10%

Therapeutic Nuclear Medicines Market
Therapeutic Nuclear Medicines Market

The global therapeutic nuclear medicine market, valued at USD 1.32 billion in 2024, is poised for significant growth over the next decade. Projected to expand at a Compound Annual Growth Rate (CAGR) of 4.1% from 2024 to 2034, the market is expected to reach a valuation of USD 1.97 billion by 2034.

The growth of the therapeutic nuclear medicine market is driven by increasing adoption of targeted radiopharmaceutical therapies for cancer and other chronic diseases. These therapies offer precision treatment by delivering radioactive isotopes directly to affected tissues, minimizing damage to surrounding healthy cells.

Key factors fueling market expansion include advancements in nuclear medicine technology, rising prevalence of cancer and cardiovascular diseases, and increasing investment in radiopharmaceutical R&D. Regulatory support for innovative therapies and expanding applications in personalized medicine are further boosting the market outlook.

As healthcare systems worldwide focus on precision oncology and tailored treatments, the therapeutic nuclear medicine market is set for sustained growth, offering promising solutions for complex medical conditions.

Key Growth Drivers

The growth of the therapeutic nuclear medicine market is influenced by several factors:

  • Increasing Incidence of Cancer: The rising number of cancer cases globally is a significant driver, as therapeutic nuclear medicine plays a crucial role in treating various cancers, particularly thyroid cancer.
  • Advancements in Nuclear Medicine Technology: Innovations in radiopharmaceuticals and imaging techniques are enhancing the effectiveness and safety of nuclear medicine therapies.

Market Dynamics

  • The market is characterized by the use of radioactive materials for both diagnostic and therapeutic purposes, with a growing emphasis on personalized medicine.
  • Increased awareness and acceptance of nuclear medicine therapies among healthcare providers and patients are contributing to market expansion.

Regional Insights

  • North America is expected to dominate the therapeutic nuclear medicine market due to high healthcare spending, advanced medical infrastructure, and strong research and development activities.
  • Emerging markets in Asia-Pacific may experience significant growth driven by increasing healthcare investments and a rising burden of cancer-related diseases.

Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market

The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.

Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.

Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.

Recent Developments in the Therapeutic Nuclear Medicine Market

  • In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
  • In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
  • In January 2024, BARC’s Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India’s Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
  • In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.

Key Companies in the Therapeutic Nuclear Medicine Market

  • Bayer AG
  • GE Healthcare
  • Novartis AG
  • Cardinal Health Inc.
  • Mallinckrodt plc.
  • Lantheus Medical Imaging Inc.
  • Bracco Imaging S.p.A
  • Eckert & Ziegler
  • Curium Pharma
  • International Isotopes Idaho, Inc.
  • Medi-Radiopharma Co., Ltd.

A Full Report Overview

Key Segments

By Treatment Type:

  • Radium-223
  • Iodine-131
  • Leutitium-177
  • Yttrium-90
  • Samarium-153
  • Strontium-89
  • Rhenium-188+Rhenium-186
  • Erbium- 169
  • Phosphorous-32
  • Others

By Indication:

  • Prostate Cancer
  • Painful Bone Metastases
  • Thyroid Cancer
  • Neuroblastoma
  • Synovitis
  • Non-Hodgkin’s Lymphoma
  • Hepatic Metastases
  • Brain Tumour
  • Others

By Distribution Channel:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Advanced Wound Management Market to Reach USD 11.5 Billion by 2033, Growing at a 3.6% CAGR

Advanced Wound Management Market
Advanced Wound Management Market

The global advanced wound management market is projected to grow steadily, with an estimated valuation of USD 8.1 billion in 2023. According to Future Market Insights (FMI), the market is anticipated to reach USD 11.5 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period.

The growth of the advanced wound management market is driven by the rising prevalence of chronic wounds, including diabetic ulcers, pressure sores, and post-surgical wounds. Increasing awareness about advanced wound care solutions and their ability to improve healing outcomes has accelerated their adoption in healthcare settings worldwide.

Advancements in wound care technologies, such as bioactive dressings, antimicrobial products, and negative pressure wound therapy (NPWT), are also playing a pivotal role in boosting market growth. These solutions offer faster recovery times, reduced infection risks, and improved patient comfort, making them highly sought after in clinical and home care settings.

As healthcare providers emphasize patient-centric care and cost-effective solutions, the advanced wound management market is set to witness sustained growth over the coming decade.

Key Growth Drivers

Several factors are driving the growth of the advanced wound management market:

  • Increasing Incidence of Chronic Wounds: The rising prevalence of conditions such as diabetes and obesity leads to a higher incidence of chronic wounds, necessitating effective management solutions.
  • Technological Advancements: Innovations in wound care technologies, including negative pressure wound therapy (NPWT) and advanced wound dressings, are enhancing treatment outcomes and patient comfort.

Market Dynamics

  • The market is characterized by a variety of products, including advanced wound dressings, wound care devices, and active wound care solutions. Advanced wound dressings are expected to dominate the market due to their effectiveness in managing exudate and promoting healing.
  • The growing geriatric population, which typically has slower healing capabilities, further elevates the demand for advanced wound management products.

Regional Insights

  • The North American region is anticipated to hold a significant share of the market, driven by high healthcare spending and advanced medical infrastructure.
  • Emerging markets in Asia-Pacific are also expected to witness substantial growth due to increasing healthcare investments and rising awareness about advanced wound care technologies.

Competitive Landscape

The present number of key players consolidates the market. These players launch new products in the global market to acquire maximum output and satisfy end users’ requirements. In addition, their advanced technologies, initiative plans, and huge investment in research and development activities upsurge the market expansion further.

Marketing strategies followed by these key players include mergers, agreements, collaborations, acquisitions, partnerships, and product launches. As a result, their innovation in the healthcare sector collects huge revenue in the global market.

Other Prominent Players in the Market are

  • B. Braun Melsungen AG
  • Mölnlycke Health Care
  • ConvaTec Group plc
  • Coloplast A/S, SIGVARIS
  • Acelity L.P. Inc.
  • 3M
  • BSN Medical
  • Ethicon Inc.
  • Medline Industries, Inc.
  • Smith & Nephew PLC.

Recent Developments in the Global Market are:

  • In March 2021, B. Braun Avitum AG, a global manufacturer of medical devices and pharmaceutical products, collaborated with CytoSorbents Corporation, a critical care immunotherapy leader. The collaboration was aimed to promote a global co-marketing agreement regarding sales of CytoSorb blood purification technology to treat inflammation.
  • In January 2020, ConvaTec Group Plc announced the release of its new ConvaMax superabsorber wound dressing. ConvaMax superabsorber dressing is applied in highly exuding wounds such as leg ulcers, diabetic foot ulcers, pressure ulcers, and surgical wounds.

Full Report Revealed

Advanced Wound Management Market by Category

By Product Type:

  • Advance Wound Dressings
  • Foam
  • Hydrocolloid
  • Hydrofiber
  • Film
  • Alginate
  • Hydrogel
  • Collagen
  • Wound Contact Layer
  • Superabsorbent Dressings
  • NPWT Devices
  • Standalone NPWT Devices
  • Single Use Disposable NPWT Devices
  • Portable NPWT Devices
  • NPWT Accessories

By Application:

  • Chronic Ulcers
  • Venous Leg Ulcers
  • Diabetic Foot Ulcers
  • Pressure Ulcers
  • Non-healing Surgical Wounds
  • Traumatic Wounds
  • Burn Cases

By End User:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Skilled Nursing Facilities
  • Other Facilities

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Bioimpedance Devices Market to Reach USD 1.24 Billion by 2034, Growing at 6.7% CAGR

Bioimpedance Devices Market
Bioimpedance Devices Market

The global bioimpedance devices market is on a steady growth trajectory, with estimated sales of USD 650.5 million in 2024. The market is projected to expand at a robust Compound Annual Growth Rate (CAGR) of 6.7% between 2024 and 2034, reaching a valuation of USD 1,244.2 million by 2034. Revenue generated by bioimpedance devices in 2023 stood at USD 612.3 million.

Bioimpedance devices, widely used for body composition analysis, hydration status monitoring, and various diagnostic applications, are gaining traction due to their non-invasive nature and increasing demand in healthcare and fitness industries. The growing emphasis on personalized healthcare, combined with rising health awareness among individuals, is driving the adoption of these devices.

Technological advancements in bioimpedance systems are further enhancing accuracy and usability, contributing to market growth. The expanding application scope in chronic disease management, sports medicine, and wellness monitoring is expected to create significant opportunities for manufacturers in the coming decade.

Key Growth Drivers

The expansion of the bioimpedance devices market is driven by several factors:

  • Rising Prevalence of Chronic Diseases: The increasing incidence of conditions such as cardiovascular disorders, diabetes, and obesity necessitates continuous monitoring of body composition and fluid levels.
  • Technological Advancements: Innovations have made bioimpedance devices more accurate, user-friendly, and cost-effective, broadening their accessibility to healthcare facilities.

Market Dynamics

  • The growing awareness among consumers regarding the importance of regular health check-ups and personalized healthcare is contributing to market growth.
  • The effectiveness of bioimpedance devices in non-invasive body composition analysis and fluid monitoring further enhances their appeal in clinical settings.

Regional Insights

  • The market is particularly strong in developed regions where healthcare infrastructure supports advanced monitoring technologies.
  • Favorable government initiatives and funding for research and development in medical technologies are also boosting market growth.

Competitive Landscape

Substantial investments are seen in the bioimpedance devices industry towards research and development in order to drive innovations by differentiating products through advanced features and improved patient outcomes. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.

Recent Industry Developments in Bioimpedance Devices Market:

  • In December 2023, AMPED FITNESS® partnered with Evolt™ to bring Vip Members Top-Tier Body Composition Technology. The Evolt 360 Body Composition Scanner is a simple-to-use tool that provides detailed data about the body through more than 40 measurements in just 60 seconds. It works by passing a safe electrical current through the feet and hands to measure muscle mass, fat mass, water and minerals in a way that is specific to the individual
  • Omron Corporation strategically focuses on leveraging advanced bioimpedance technology to enhance diagnostic accuracy and patient monitoring. By integrating cutting-edge innovations, expanding global partnerships, and prioritizing user-friendly, reliable solutions, Omron aims to lead the bioimpedance devices market.

A Full Report Analysis

Key Players of Bioimpedance Devices Market

  • Bioparhom
  • Akern
  • Biodynamics Corporation
  • Tanita Corporation
  • Biotekna
  • Omron Corporation
  • InBody
  • EVOLT 360
  • RJL Systems
  • Fook Tin Group Holding Ltd

Key Segments of Bioimpedance Devices Market

By Product:

In terms of product, the industry is divided into multi-frequency, single-frequency and dual-frequency.

By Modality:

In terms of modality, the industry is segregated into wired bioimpedance and wireless bioimpedance.

By Application:

In terms of application, the industry is segregated into whole-body measurement and segmental body measurement.

By Region:

Key countries of North America, Latin America, Western Europe, Eastern, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube